A B-cell developmental gene regulatory network is activated in infant AML

Infant Acute Myeloid Leukemia (AML) is a poorly-addressed, heterogeneous malignancy distinguished by surprisingly few mutations per patient but accompanied by myriad age-specific translocations. These characteristics make treatment of infant AML challenging. While infant AML is a relatively rare dis...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hamid Bolouri, Rhonda Ries, Laura Pardo, Tiffany Hylkema, Wanding Zhou, Jenny L. Smith, Amanda Leonti, Michael Loken, Jason E. Farrar, Timothy J. Triche, Soheil Meshinchi
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/d13c5f80eaca472491942928dac038df
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d13c5f80eaca472491942928dac038df
record_format dspace
spelling oai:doaj.org-article:d13c5f80eaca472491942928dac038df2021-11-25T06:19:44ZA B-cell developmental gene regulatory network is activated in infant AML1932-6203https://doaj.org/article/d13c5f80eaca472491942928dac038df2021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601427/?tool=EBIhttps://doaj.org/toc/1932-6203Infant Acute Myeloid Leukemia (AML) is a poorly-addressed, heterogeneous malignancy distinguished by surprisingly few mutations per patient but accompanied by myriad age-specific translocations. These characteristics make treatment of infant AML challenging. While infant AML is a relatively rare disease, it has enormous impact on families, and in terms of life-years-lost and life limiting morbidities. To better understand the mechanisms that drive infant AML, we performed integrative analyses of genome-wide mRNA, miRNA, and DNA-methylation data in diagnosis-stage patient samples. Here, we report the activation of an onco-fetal B-cell developmental gene regulatory network in infant AML. AML in infants is genomically distinct from AML in older children/adults in that it has more structural genomic aberrations and fewer mutations. Differential expression analysis of ~1500 pediatric AML samples revealed a large number of infant-specific genes, many of which are associated with B cell development and function. 18 of these genes form a well-studied B-cell gene regulatory network that includes the epigenetic regulators BRD4 and POU2AF1, and their onco-fetal targets LIN28B and IGF2BP3. All four genes are hypo-methylated in infant AML. Moreover, micro-RNA Let7a-2 is expressed in a mutually exclusive manner with its target and regulator LIN28B. These findings suggest infant AML may respond to bromodomain inhibitors and immune therapies targeting CD19, CD20, CD22, and CD79A.Hamid BolouriRhonda RiesLaura PardoTiffany HylkemaWanding ZhouJenny L. SmithAmanda LeontiMichael LokenJason E. FarrarTimothy J. TricheSoheil MeshinchiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Hamid Bolouri
Rhonda Ries
Laura Pardo
Tiffany Hylkema
Wanding Zhou
Jenny L. Smith
Amanda Leonti
Michael Loken
Jason E. Farrar
Timothy J. Triche
Soheil Meshinchi
A B-cell developmental gene regulatory network is activated in infant AML
description Infant Acute Myeloid Leukemia (AML) is a poorly-addressed, heterogeneous malignancy distinguished by surprisingly few mutations per patient but accompanied by myriad age-specific translocations. These characteristics make treatment of infant AML challenging. While infant AML is a relatively rare disease, it has enormous impact on families, and in terms of life-years-lost and life limiting morbidities. To better understand the mechanisms that drive infant AML, we performed integrative analyses of genome-wide mRNA, miRNA, and DNA-methylation data in diagnosis-stage patient samples. Here, we report the activation of an onco-fetal B-cell developmental gene regulatory network in infant AML. AML in infants is genomically distinct from AML in older children/adults in that it has more structural genomic aberrations and fewer mutations. Differential expression analysis of ~1500 pediatric AML samples revealed a large number of infant-specific genes, many of which are associated with B cell development and function. 18 of these genes form a well-studied B-cell gene regulatory network that includes the epigenetic regulators BRD4 and POU2AF1, and their onco-fetal targets LIN28B and IGF2BP3. All four genes are hypo-methylated in infant AML. Moreover, micro-RNA Let7a-2 is expressed in a mutually exclusive manner with its target and regulator LIN28B. These findings suggest infant AML may respond to bromodomain inhibitors and immune therapies targeting CD19, CD20, CD22, and CD79A.
format article
author Hamid Bolouri
Rhonda Ries
Laura Pardo
Tiffany Hylkema
Wanding Zhou
Jenny L. Smith
Amanda Leonti
Michael Loken
Jason E. Farrar
Timothy J. Triche
Soheil Meshinchi
author_facet Hamid Bolouri
Rhonda Ries
Laura Pardo
Tiffany Hylkema
Wanding Zhou
Jenny L. Smith
Amanda Leonti
Michael Loken
Jason E. Farrar
Timothy J. Triche
Soheil Meshinchi
author_sort Hamid Bolouri
title A B-cell developmental gene regulatory network is activated in infant AML
title_short A B-cell developmental gene regulatory network is activated in infant AML
title_full A B-cell developmental gene regulatory network is activated in infant AML
title_fullStr A B-cell developmental gene regulatory network is activated in infant AML
title_full_unstemmed A B-cell developmental gene regulatory network is activated in infant AML
title_sort b-cell developmental gene regulatory network is activated in infant aml
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/d13c5f80eaca472491942928dac038df
work_keys_str_mv AT hamidbolouri abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT rhondaries abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT laurapardo abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT tiffanyhylkema abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT wandingzhou abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT jennylsmith abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT amandaleonti abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT michaelloken abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT jasonefarrar abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT timothyjtriche abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT soheilmeshinchi abcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT hamidbolouri bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT rhondaries bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT laurapardo bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT tiffanyhylkema bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT wandingzhou bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT jennylsmith bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT amandaleonti bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT michaelloken bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT jasonefarrar bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT timothyjtriche bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
AT soheilmeshinchi bcelldevelopmentalgeneregulatorynetworkisactivatedininfantaml
_version_ 1718413893727944704